Search results for "Albumins"

showing 10 items of 71 documents

Absorption And Transferring Of The Coghlear Fluids

1968

The perilymph is absorbed in the loose connective tissue of the modio-lum, the endolymph is absorbed in the planum limbi and the interstitial liquid of the organ of Corti in the inner spiral sulcus. The basin of the vein of the aqueduct of the cochlea in a fetal phase transfers almost only perilymph. When fully developed, many veins of the above-said basin are obliterated and the remaining ones transfer more blood than perilymph. From the interstitial spaces of the limbus the endolymph flows into the capillaries towards the inner auditory veins and the interstitial liquid of the organ of Corti flows towards the same veins by means of short lymphatic vessels.

EndolymphAbsorptionVeinsfluids and secretionsInterstitial spacePregnancyAlbuminsotorhinolaryngologic diseasesmedicineHumansVeinCochleaLoose connective tissueChemistryLabyrinthine FluidsGeneral MedicineAnatomyPerilymphCochleamedicine.anatomical_structureLymphatic systemOtorhinolaryngologyOrgan of Corticardiovascular systemFemalesense organsActa Oto-Laryngologica
researchProduct

Native-state pea albumin and globulin behavior upon transglutaminase treatment

2015

International audience; The behavior of pea albumin (Alb) and globulin (Glob) in their native state upon microbial transglutaminase (MTGase) treatment was studied. Only Glob was able to form a gel, at up to a 10% (w/w) concentration, with a minimum gelling concentration of 6% (w/w), and with a cross-linking degree of 25%. The most affected Glob subunits were convicilin (71 kDa), vicilins (55, 50, and 35 kDa), and legumin acidic subunit (40 kDa). In contrast, the legumin basic subunit (20 kDa) and vicilins of molecular weight less than 20 kDa remained mostly intact in all studied conditions. The cross-linking degree of Alb was 12%, which was not sufficient to form MTGase-induced gel. Major a…

GlobulinTissue transglutaminaseProtein subunitBioengineering01 natural sciencesApplied Microbiology and BiotechnologyBiochemistry0404 agricultural biotechnologyNative stateLeguminPea albuminsDenaturation (biochemistry)[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyCross-linking degreebiologyChemistry010401 analytical chemistryAlbuminglob (programming)04 agricultural and veterinary sciences040401 food scienceOptimum parameters0104 chemical sciencesBiochemistryPea globulinsbiology.proteinMicrobial transglutaminase properties
researchProduct

Glycation alters ligand binding, enzymatic, and pharmacological properties of human albumin.

2015

Albumin, the major circulating protein in blood plasma, can be subjected to an increased level of glycation in a diabetic context. Albumin exerts crucial pharmacological activities through its drug binding capacity, i.e., ketoprofen, and via its esterase-like activity, allowing the conversion of prodrugs into active drugs. In this study, the impact of the glucose-mediated glycation on the pharmacological and biochemical properties of human albumin was investigated. Aggregation product levels and the redox state were quantified to assess the impact of glycation-mediated changes on the structural properties of albumin. Glucose-mediated changes in ketoprofen binding properties and esterase-lik…

Glycation End Products AdvancedGlycosylationGlycosylationSerum albuminContext (language use)Plasma protein bindingProtein aggregationBiochemistryChromatography AffinityMass SpectrometryProtein Structure Secondarychemistry.chemical_compoundGlycationAlbuminsBlood plasmaHumansGlycated Serum AlbuminSerum AlbuminbiologyAlbuminAlbuminSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)Spectrometry FluorescencechemistryBiochemistryKetoprofenbiology.proteinHumanProtein BindingBiochemistry
researchProduct

The influence of advanced glycation endproducts (AGE) on the expression of human endothelial adhesion molecules.

1998

Advanced glycation endproducts (AGEs) possibly play a dominant role in the pathogenesis of macrovascular disease in diabetes. Recent studies could demonstrate that glycated albumin (AGE-BSA) was able to stimulate vascular cell adhesion molecule-1 (VCAM.1) on endothelial cells. The aim of this study was to find out if AGE-BSA was not only able to enhance the expression of vascular cell adhesion molecule-1, but also of intercellular adhesion molecule-1 (ICAM-1) and E-Selectin on human endothelial cells. Stimulation of endothelial cells with AGE-BSA for six hours predominantly increased the expression of VCAM-1, but ICAM-1 and E-Selectin were also upregulated as shown by immunoilluminometric a…

Glycation End Products AdvancedTranscription GeneticEndocrinology Diabetes and MetabolismIntercellular Adhesion Molecule-1Gene ExpressionVascular Cell Adhesion Molecule-1BiologyPolymerase Chain ReactionEndocrinologyGlycationAlbuminsE-selectinInternal MedicinemedicineHumansCell adhesionMacrovascular diseaseDose-Response Relationship DrugCell adhesion moleculeGeneral MedicineAdhesionmedicine.diseaseIntercellular Adhesion Molecule-1ImmunohistochemistryEndothelial stem cellImmunologyLuminescent Measurementsbiology.proteinCancer researchEndothelium VascularE-SelectinExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct

Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing…

2017

Background: Currently, no unequivocal predictors of disease evolution exist in patients with multiple sclerosis (MS). Cortical atrophy measurements are, however, closely associated with cumulative disability. Objective: Here, we aim to forecast longitudinal magnetic resonance imaging (MRI)-driven cortical atrophy and clinical disability from cerebrospinal fluid (CSF) markers. Methods: We analyzed CSF fractions of albumin and immunoglobulins (Ig) A, G, and M and their CSF to serum quotients. Results: Widespread atrophy was highly associated with increased baseline CSF concentrations and quotients of albumin and IgA. Patients with increased CSFIgA and CSFIgM showed higher functional disabilit…

Immunoglobulin AAdultMalePathologymedicine.medical_specialty03 medical and health sciencesYoung Adult0302 clinical medicineCerebrospinal fluidMultiple Sclerosis Relapsing-RemittingAlbuminsmedicineHumansIn patient030212 general & internal medicineLongitudinal StudiesCortical atrophyCerebral Cortexbiologybusiness.industryMultiple sclerosisAlbuminmedicine.diseasePrognosisImmunoglobulin ADisease evolutionNeurologyRelapsing remittingbiology.proteinFemaleNeurology (clinical)Atrophybusiness030217 neurology & neurosurgeryBiomarkersMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Dominant negative MORT1/FADD rescues mice from CD95 and TNF-induced liver failure

2002

Derangement of the apoptotic program is considered an important cause of liver disease. It became clear that receptor-mediated apoptosis is of specific interest in this context, and CD95 and CD120a, both members of the tumor necrosis factor (TNF) receptor superfamily, are the most prominent cell death receptors involved. The death signal is induced upon ligand binding by recruitment of caspases via the adapter molecule MORT1/FADD to the receptor and their subsequent activation. To investigate the role of MORT1/FADD in hepatocyte apoptosis, we generated transgenic mice expressing liver-specific dominant negative mutant. Mice looked grossly normal; breeding and liver development were not diff…

Lipopolysaccharidesmedicine.medical_specialtyProgrammed cell deathFas-Associated Death Domain ProteinOligonucleotidesMice TransgenicAntibodiesReceptors Tumor Necrosis FactorMiceLiver diseaseAntigens CDAlbuminsInternal medicinemedicineAnimalsfas ReceptorFADDPromoter Regions GeneticAdaptor Proteins Signal TransducingLiver injuryHepatitisMice Inbred BALB CHepatologybiologyTumor Necrosis Factor-alphamedicine.diseaseFas receptorMice Inbred C57BLEndocrinologyReceptors Tumor Necrosis Factor Type IApoptosisCaspasesbiology.proteinTumor necrosis factor alphaCarrier ProteinsLiver FailureHepatology
researchProduct

12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombo…

2015

Background: A 24-48-week course of interferon-based therapy poorly tolerated in hepatitis C virus (HCV) cirrhosis patients with thrombocytopenia. Aim of the study was to identify patients at low-risk of liver-related complications over a 12-week course of interferon-based therapy. Methods: We assessed the rate of complications and death during the first 12 weeks of interferon-based therapy in HCV cirrhotics with thrombocytopenia (platelets ≤75×109/L) enrolled in the ENABLE-1 and -2 phase 3 randomised controlled trials. Results: Overall, among 1441 patients, 89 complications (6.9%) and 10 deaths (0.7%) were observed within the first 12 weeks of therapy. At univariate analysis baseline albumi…

Liver CirrhosisMaleCirrhosisHepacivirusmedicine.disease_causeGastroenterologyBenzoatesSeverity of Illness IndexLiver-related complicationchemistry.chemical_compoundModel for End-Stage Liver DiseaseRisk FactorsAlbumin levelHydrazineMultivariate AnalysiAged 80 and overUnivariate analysisGastroenterologyHepatitis CMiddle AgedHydrazinesTreatment OutcomeFemaleHumanAdultmedicine.medical_specialtyLiver CirrhosiHepatitis C virusEltrombopagAlpha interferonAntiviral AgentsBenzoateInternal medicineAlbuminsRibavirinmedicineHumansLiver-related mortalityAgedAntiviral AgentHepaciviruHepatologybusiness.industryAlbuminRisk FactorRibavirinMELD scoreInterferon-alphaHepatitis C Chronicmedicine.diseaseThrombocytopeniaSurgerychemistryPyrazoleMultivariate AnalysisPyrazolesbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

2018

Background Evidence is scarce on the efficacy of long-term human albumin (HA) administration in patients with decompensated cirrhosis. The human Albumin for the treatmeNt of aScites in patients With hEpatic ciRrhosis (ANSWER) study was designed to clarify this issue. Methods We did an investigator-initiated multicentre randomised, parallel, open-label, pragmatic trial in 33 academic and non-academic Italian hospitals. We randomly assigned patients with cirrhosis and uncomplicated ascites who were treated with anti-aldosteronic drugs (≥200 mg/day) and furosemide (≥25 mg/day) to receive either standard medical treatment (SMT) or SMT plus HA (40 g twice weekly for 2 weeks, and then 40 g weekly…

Liver CirrhosisMaleTime FactorsCirrhosisKaplan-Meier Estimatelaw.inventionascites0302 clinical medicineHepatorenal syndromeRandomized controlled trialFurosemidelawAscitesClinical endpointParacentesisDiureticsalbumin decompensated cirrhosiMineralocorticoid Receptor AntagonistsSettore MED/12 - GastroenterologiaMedicine (all)Hazard ratioGeneral MedicineMiddle AgedSurvival RateCirrhosis030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyQuality-Adjusted Life Yearsmedicine.symptomHyponatremiamedicine.medical_specialty03 medical and health sciencesAlbuminsInternal medicinemedicineHumansSurvival ratealbuminAgedbusiness.industrycirrhosis; albumin; ascitesmedicine.diseaseClinical trialalbumin cirrhosis ascites liver decompensationQuality of LifeHyperkalemiabusinessEsophagus Varices Portal Hypertension Varicosis
researchProduct

Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid

2022

Background & Aims Obeticholic acid (OCA) has recently been restricted in patients with primary biliary cholangitis (PBC) with "advanced cirrhosis" because of its narrow therapeutic index. We aimed to better define the predicting factors of hepatic serious adverse events (SAEs) and non-response in cirrhotic patients undergoing OCA therapy. Methods Safety and efficacy of treatment were evaluated in a cohort of consecutive PBC cirrhotic patients started with OCA. OCA response was evaluated according to the Poise criteria. Risk factors for hepatic SAEs and non-response were reported as risk ratios (RR) with 95% confidence intervals (CIs). Results One hundred PBC cirrhotics were included, 97…

Liver CirrhosisMaleliver decompensationsafetyHepatologyLiver Cirrhosis Biliarydecision curve analysis; efficacy; liver decompensation; safety; total bilirubin; Albumins; Ascites; Bilirubin; Chenodeoxycholic Acid; Humans; Liver Cirrhosis; Male; Liver Cirrhosis BiliaryBiliaryefficacyAscitesBilirubinChenodeoxycholic Acidtotal bilirubindecision curve analysiSettore MED/12AlbuminsHumansdecision curve analysis
researchProduct

Biodegradable Protein Nanocontainers

2015

The application of synthetic polymers for drug delivery often requires tremendous efforts to ensure biocompatibility and -degradation. To use the body's own substances can help to overcome these problems. Herein, we present the first synthesis of nanocontainers entirely composed of albumin proteins. These protein nanocontainers (PNCs) were loaded with hydrophilic compounds and release of the payload is triggered through natural lysis in vitro in human monocyte-derived dendritic cells (moDCs). No aggregation of PNCs in human blood plasma was observed, indicating stability for blood circulation. As the PNCs were readily taken up by moDCs, they are considered as a promising delivery platform f…

LysisPolymers and PlasticsBiocompatibilityHuman bloodProtein StabilityChemistryAlbuminBioengineeringNanotechnologyDendritic CellsBiomaterialsNanocapsulesAlbuminsDelayed-Action PreparationsBlood circulationProteolysisDrug deliveryMaterials ChemistryHumansHydrophobic and Hydrophilic InteractionsCells CulturedFluorescent DyesBiomacromolecules
researchProduct